tetano
Editor, Senior Moderator
Clin Respir J
. 2025 Apr;19(4):e70050.
doi: 10.1111/crj.70050. Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study
Jeffrey Weinstein[SUP] 1 [/SUP], Nikhil Jagan[SUP] 2 [/SUP], Shawnta Lorthridge-Jackson[SUP] 3 [/SUP], J E Hamer-Maansson[SUP] 3 [/SUP], Peg Squier[SUP] 3 [/SUP]
Affiliations
Introduction: This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID-19-associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Methods: Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician-assessed clinical benefit, and serious adverse event (SAE) incidence.
Results: Of 312 patients, 45.5% achieved ≥ 1-point clinical status improvement. Physician-assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related.
Conclusions: Overall, some hospitalized patients with COVID-19-associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated.
Trial registration: ClinicalTrials.gov identifier: NCT04355793.
Keywords: COVID‐19; Janus kinase inhibitors; acute respiratory distress syndrome; cytokine release syndrome; expanded access; hospitalization.
. 2025 Apr;19(4):e70050.
doi: 10.1111/crj.70050. Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study
Jeffrey Weinstein[SUP] 1 [/SUP], Nikhil Jagan[SUP] 2 [/SUP], Shawnta Lorthridge-Jackson[SUP] 3 [/SUP], J E Hamer-Maansson[SUP] 3 [/SUP], Peg Squier[SUP] 3 [/SUP]
Affiliations
- PMID: 40197709
- PMCID: PMC11976455
- DOI: 10.1111/crj.70050
Introduction: This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID-19-associated cytokine storm in patients eligible for hospitalization (NCT04355793).
Methods: Patients received ruxolitinib 5 mg twice daily (preferred regimen when tolerated) or once daily for ≤ 14 days, or until determination of no clinical benefit was made. Outcomes were clinical status, physician-assessed clinical benefit, and serious adverse event (SAE) incidence.
Results: Of 312 patients, 45.5% achieved ≥ 1-point clinical status improvement. Physician-assessed clinical benefit was reported in 42.6% of evaluable patients. SAEs occurred in 42.9%, with 2.6% experiencing an SAE suspected to be ruxolitinib related.
Conclusions: Overall, some hospitalized patients with COVID-19-associated cytokine storm who received ruxolitinib experienced clinical status improvement; ruxolitinib was well tolerated.
Trial registration: ClinicalTrials.gov identifier: NCT04355793.
Keywords: COVID‐19; Janus kinase inhibitors; acute respiratory distress syndrome; cytokine release syndrome; expanded access; hospitalization.